Cargando…

Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors

PURPOSE: To describe the case of a patient with a recurrent large myopic macular hole (MH), who was successfully treated with a plasma rich in growth factors (PRGF) membrane. CASE REPORT: A 71-year-old patient presented a myopic MH in his right eye. One month later, pars plana vitrectomy with intern...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Ávila, Ronald M, Fernández-Vega González, Álvaro, Fernández-Vega Sanz, Álvaro, Merayo-Lloves, Jesús
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634266/
https://www.ncbi.nlm.nih.gov/pubmed/31372064
http://dx.doi.org/10.2147/IMCRJ.S170329
_version_ 1783435752521072640
author Sánchez-Ávila, Ronald M
Fernández-Vega González, Álvaro
Fernández-Vega Sanz, Álvaro
Merayo-Lloves, Jesús
author_facet Sánchez-Ávila, Ronald M
Fernández-Vega González, Álvaro
Fernández-Vega Sanz, Álvaro
Merayo-Lloves, Jesús
author_sort Sánchez-Ávila, Ronald M
collection PubMed
description PURPOSE: To describe the case of a patient with a recurrent large myopic macular hole (MH), who was successfully treated with a plasma rich in growth factors (PRGF) membrane. CASE REPORT: A 71-year-old patient presented a myopic MH in his right eye. One month later, pars plana vitrectomy with internal limiting membrane (ILM) peeling was performed, achieving closure of the MH. Three months later a recurrence was observed (700 µm) without visual acuity (VA) improvement. A new surgery was carried out placing an autologous PRGF-membrane into the MH, and performing a fluid-gas exchange at the end of the surgery. After two months of follow-up, the MH was completely closed, obtaining the anatomic recovery of the foveal depression, and improving the VA to 0.1. No adverse reactions were associated with the use of PRGF and there were no new recurrences of the MH in a follow-up period of six months. CONCLUSION: The use of PRGF-membrane can be used as adjunctive therapy in the surgical repair of recurrent large myopic MHs, thus improving anatomic and visual outcomes.
format Online
Article
Text
id pubmed-6634266
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66342662019-08-01 Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors Sánchez-Ávila, Ronald M Fernández-Vega González, Álvaro Fernández-Vega Sanz, Álvaro Merayo-Lloves, Jesús Int Med Case Rep J Case Report PURPOSE: To describe the case of a patient with a recurrent large myopic macular hole (MH), who was successfully treated with a plasma rich in growth factors (PRGF) membrane. CASE REPORT: A 71-year-old patient presented a myopic MH in his right eye. One month later, pars plana vitrectomy with internal limiting membrane (ILM) peeling was performed, achieving closure of the MH. Three months later a recurrence was observed (700 µm) without visual acuity (VA) improvement. A new surgery was carried out placing an autologous PRGF-membrane into the MH, and performing a fluid-gas exchange at the end of the surgery. After two months of follow-up, the MH was completely closed, obtaining the anatomic recovery of the foveal depression, and improving the VA to 0.1. No adverse reactions were associated with the use of PRGF and there were no new recurrences of the MH in a follow-up period of six months. CONCLUSION: The use of PRGF-membrane can be used as adjunctive therapy in the surgical repair of recurrent large myopic MHs, thus improving anatomic and visual outcomes. Dove 2019-07-12 /pmc/articles/PMC6634266/ /pubmed/31372064 http://dx.doi.org/10.2147/IMCRJ.S170329 Text en © 2019 Sánchez-Ávila et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Sánchez-Ávila, Ronald M
Fernández-Vega González, Álvaro
Fernández-Vega Sanz, Álvaro
Merayo-Lloves, Jesús
Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title_full Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title_fullStr Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title_full_unstemmed Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title_short Treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
title_sort treatment of recurrent myopic macular hole using membrane of plasma rich in growth factors
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6634266/
https://www.ncbi.nlm.nih.gov/pubmed/31372064
http://dx.doi.org/10.2147/IMCRJ.S170329
work_keys_str_mv AT sanchezavilaronaldm treatmentofrecurrentmyopicmacularholeusingmembraneofplasmarichingrowthfactors
AT fernandezvegagonzalezalvaro treatmentofrecurrentmyopicmacularholeusingmembraneofplasmarichingrowthfactors
AT fernandezvegasanzalvaro treatmentofrecurrentmyopicmacularholeusingmembraneofplasmarichingrowthfactors
AT merayollovesjesus treatmentofrecurrentmyopicmacularholeusingmembraneofplasmarichingrowthfactors